Argus Downgrades Pfizer (PFE) to Hold
- Wall Street rises, buoyed by economic data; Dow sets high
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Amazon (AMZN) Could Open Over 2,000 Brick-and Mortar Groceries if Tests Succeed - DJ; Kroger (KR) on Watch
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- After-Hours Stock Movers 12/05: (TXMD) (COUP) (BOBE) Higher; (SB) (LXRX) (STWD) Lower (more...)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Argus downgraded Pfizer (NYSE: PFE) from Buy to Hold on a weaker outlook.
The analyst no longer expect PFE to achieve their former target price of $39 given recent pipeline setbacks, prospects for increased competition, and management’s decision to shelve its business separation plan.
The firm is lowering 2016 EPS estimate to $2.40 from $2.47, due mainly to the cancellation of Phase 3 trials of the company’s cholesterol-lowering drug. They are also lowering 2017 estimate to $2.57 from $2.65 based on expectations for higher costs and increased competition next year.
Shares of Pfizer closed at $31.07 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Goldman Sachs Downgrades Marvell (MRVL) to Sell
- MKM Partners Favors Asset-Light Lodging Stocks; Updates Ratings - (BEL) (CHH) (H) (HLT) (IHG) (MAR) (STAY) (WYN)
- Jefferies Raises Price Target on Parker-Hannifin (PH) Ahead of Acquisition Close
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!